ASCO Panel Sees Greater Utility for Bone-Modifying Agents in Myeloma

Jason Harris
Published: Thursday, May 17, 2018
Kenneth C. Anderson, MD

Kenneth C. Anderson, MD
In updated guidelines exploring the role of bone-modifying agents, the American Society of Clinical Oncology (ASCO) has recommended expanding the use of bisphosphonates to include all patients being treated for active multiple myeloma.1

Table. Denosumab Demonstrates Noninferiority to Zoledronic Acid in Time to First Skeletal Event5

Dosing Changes Discussed

The updated guidelines also discuss the feasibility of less-frequent dosing of bone-targeted treatments in selected patients, given the risk of osteonecrosis of the jaw (ONJ) associated with bone-targeting agents. Study results have shown that less-frequent dosing can reduce the risk.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication